Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors

Mascarenhas, Leo; Dubois, Steven G.; Albert, Catherine M.; Bielack, Stefan; Orbach, Daniel; Federman, Noah; Geoerger, Birgit; Nagasubramanian, Ramamoorthy; Zhang, Yizhou; Chisholm, Julia; Melcon, Soledad Gallego; Goto, Hiroaki; Morgenstern, Daniel A.; Owens, Cormac; Pappo, Alberto S.; Perreault, Sebastien; Schulte, Johannes H.; Shukla, Neerav; Zwaan, Christian Michel; Neu, Natascha; Bernard-Gauthier, Vadim; de la Cuesta, Esther; van Tilburg, Cornelis M.; Laetsch, Theodore W.

Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors

Autor(en):

Mascarenhas, Leo; Dubois, Steven G.; Albert, Catherine M.; Bielack, Stefan; Orbach, Daniel; Federman, Noah; Geoerger, Birgit; Nagasubramanian, Ramamoorthy; Zhang, Yizhou; Chisholm, Julia; Melcon, Soledad Gallego; Goto, Hiroaki; Morgenstern, Daniel A.; Owens, Cormac; Pappo, Alberto S.; Perreault, Sebastien; Schulte, Johannes H.; Shukla, Neerav; Zwaan, Christian Michel; Neu, Natascha; Bernard-Gauthier, Vadim; de la Cuesta, Esther; van Tilburg, Cornelis M.; Laetsch, Theodore W.

Tübinger Autor(en):

Schulte, Johannes H.

Erschienen in:

Journal of Clinical Oncology (2025), Bd. 43, H. 10, S. 1180-1187

Verlagsangabe:

Philadelphia : Lippincott Williams & Wilkins

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1200/JCO.24.00848

ISSN:

0732-183X